This website is intended for US Healthcare Professionals.

Back to Congresses

ISPOR-EU 2025

  • Nov 9 – 12, 2025
  •  |
  • Glasgow, UK
The agents listed below are currently under investigation. Their safety and efficacy have not yet been established.
Poster
Development of a Discrete Choice Experiment Survey to Assess Patient Preferences for Treatment of Metastatic Breast Cancer
D Chandiwana et al.
View Material
Poster
Real-World Burden of Illness in Patients With ER+/HER2- ABC Receiving Second-Line Treatment: Interim Results of Longitudinal Health Utility Data
P Chakraborti et al.
View Material

Arvinas Medical

You are now leaving arvinasmedical.com. Arvinas does not endorse or recommend the content in any third-party sites. Arvinas is not responsible and disclaims liability for the content, or for any viruses or similar harmful programs, that may be present on third-party pages or sites. Visits to a third-party website are at your own risk and subject to the terms and conditions and privacy policy of such site.

GO BACK
CONTINUE

Arvinas Oncology Medical

This website is intended for US Healthcare Professionals. It includes educational resources related to Arvinas’ investigational agents, research, and therapeutic areas of interest.

By selecting continue below, you acknowledge the information above and certify that you are a US Healthcare Professional (HCP).

YES, I AM AN HCP

If you are a member of the public who would like to learn more about Arvinas’ investigational drugs click below to be directed to Arvinas.com.

I AM NOT AN HCP